Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A

被引:200
作者
Kuhn, M [1 ]
机构
[1] Univ Klinikum Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany
关键词
guanylyl cyclase receptors;
D O I
10.1161/01.RES.0000094745.28948.4D
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Besides soluble guanylyl cyclase (GC), the receptor for NO, there are at least seven plasma membrane enzymes that synthesize the second-messenger cGMP. All membrane GCs (GC-A through GC-G) share a basic topology, which consists of an extracellular ligand binding domain, a short transmembrane region, and an intracellular domain that contains the catalytic (GC) region. Although the presence of the extracellular domain suggests that all these enzymes function as receptors, specific ligands have been identified for only three of them (GC-A through GC-C). GC-A mediates the endocrine effects of atrial and B-type natriuretic peptides regulating arterial blood pressure and volume homeostasis and also local antihypertrophic actions in the heart. GC-B is a specific receptor for C-type natriuretic peptide, having more of a paracrine function in vascular regeneration and endochondral ossification. GC-C mediates the effects of guanylin and uroguanylin on intestinal electrolyte and water transport and on epithelial cell growth and differentiation. GC-E and GC-F are colocalized within the same photoreceptor cells of the retina and have an important role in phototransduction. Finally, the functions of GC-D (located in the olfactory neuroepithelium) and GC-G (expressed in highest amounts in lung, intestine, and skeletal muscle) are completely unknown. This review discusses the structure and functions of membrane GCs, with special emphasis on the physiological endocrine and cardiac functions of GC-A, the regulation of hormone-dependent GC-A activity, and the relevance of alterations of the atrial natriuretic peptide/GC-A system to cardiovascular diseases.
引用
收藏
页码:700 / 709
页数:10
相关论文
共 124 条
[1]   Atrial natriuretic peptide induces natriuretic peptide receptor-cGMP-dependent protein kinase interaction [J].
Airhart, N ;
Yang, YF ;
Roberts, CT ;
Silberbach, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (40) :38693-38698
[2]   Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones [J].
Andreassi, MG ;
Del Ry, S ;
Palmieri, C ;
Clerico, A ;
Biagini, A ;
Giannessi, D .
EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (04) :407-414
[3]  
Beige J, 1997, AM J HYPERTENS, V10, P1316
[4]  
BENNETT BD, 1991, J BIOL CHEM, V266, P23060
[5]   REGULATION OF ATRIAL NATRIURETIC PEPTIDE-STIMULATED CGMP PRODUCTION IN THE INNER MEDULLA [J].
BERL, T ;
MANSOUR, J ;
VEIS, JH .
KIDNEY INTERNATIONAL, 1992, 41 (01) :37-42
[6]   DIVERSE BIOLOGICAL ACTIONS OF ATRIAL-NATRIURETIC-PEPTIDE [J].
BRENNER, BM ;
BALLERMANN, BJ ;
GUNNING, ME ;
ZEIDEL, ML .
PHYSIOLOGICAL REVIEWS, 1990, 70 (03) :665-699
[7]   Impaired vasodilator responses to atrial natriuretic peptide in essential hypertension [J].
Bulut, D ;
Potthast, R ;
Hanefeld, C ;
Schulz, T ;
Kuhn, M ;
Mügge, A .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (07) :567-573
[8]   ATRIAL-NATRIURETIC-PEPTIDE ELEVATION IN CONGESTIVE-HEART-FAILURE IN THE HUMAN [J].
BURNETT, JC ;
KAO, PC ;
HU, DC ;
HESER, DW ;
HEUBLEIN, D ;
GRANGER, JP ;
OPGENORTH, TJ ;
REEDER, GS .
SCIENCE, 1986, 231 (4742) :1145-1147
[9]   Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts [J].
Calderone, A ;
Thaik, CM ;
Takahashi, N ;
Chang, DLF ;
Colucci, WS .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :812-818
[10]   Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension [J].
Campese, VM ;
Tawadrous, M ;
Bigazzi, R ;
Bianchi, S ;
Mann, AS ;
Oparil, S ;
Raij, L .
HYPERTENSION, 1996, 28 (03) :335-340